MiMedx Group, Inc. (NASDAQ: MDXG) is a Healthcare company (Biotechnology) with a market capitalization of $464M. The Maz Rating grades it against the other companies in its sector.
MiMedx Group, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.18, MiMedx Group, Inc. trades at 1.5x sales and 2.2x book value. Over the last twelve months it generated about $305M of revenue and a net loss of $19M. It runs a gross margin of 77.3%, an operating margin of -8.3% and a net margin of -6.3%. It shows return on equity of -8.3%, return on invested capital of -9.7% and a free cash flow yield of 4.4%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 4.35. Over the past 52 weeks the share price ranged from $3.03 to $7.45, with a beta of 1.42.
MiMedx Group, Inc. does not currently pay a dividend.
15 Wall Street analyst ratings cover the stock: 12 Buy, 1 Hold and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
MiMedx Group, Inc. specializes in creating and supplying allografts derived from placental tissue, serving a diverse range of medical fields. The company employs its unique, patented PURION process to treat human placental tissues, a method crucial for manufacturing allografts that preserve the natural biological characteristics and essential regulatory proteins of the original tissue. This exclusive and patented processing technique incorporates both aseptic procedures and a final sterilization step, ensuring product safety and efficacy. Among its offerings is EpiFix, a semi-permeable membrane designed to act as a protective barrier, effectively treating persistent wounds such as diabetic foot ulcers, venous leg ulcers, and pressure sores. Another key product is AmnioFix, a protective, semi-permeable allograft made from dehydrated human amnion/chorion membrane, utilized to aid post-surgical recovery. EpiCord and AmnioCord, both derived from dehydrated human umbilical cord, function as allografts that foster a protective healing environment and are applied in both advanced wound care and surgical recovery contexts. AMNIOBURN is also a semi-permeable protective allograft specifically developed for managing partial and full-thickness burn injuries. Its flagship product, mdHACM, is a micronized, powdered version of AMNIOFIX. These products predominantly find use in healthcare sectors like wound management, burn treatment, surgical procedures, and non-operative sports medicine. Additionally, the company supplies allografts for dental uses to other manufacturers on an original equipment manufacturer (OEM) basis. Distribution of its products primarily occurs within the United States, facilitated by its own sales teams, independent agents, and various independent distributors. MiMedx Group, Inc.'s main office is located in Marietta, Georgia.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, MiMedx Group, Inc. (MDXG) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 19.3% / 30% · Interest income / Revenue 0.76% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 19.3% / 33% · Receivables / Mkt Cap (36m) 5.94% / 49% · Interest income / Revenue 0.76% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 19.3% / 33.33% · Receivables / Mkt Cap (24m) 5.94% / 33.33% · Interest income / Revenue 0.76% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 3.21% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 48.7% / 33.33% · Receivables / Avg Assets (4Q) 16.7% / 33.33% · Interest income / Revenue 0.76% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 45.7% / 33.33% · (Cash+Recv) / Total Assets 59.7% / 33.33% · Interest income / Revenue 0.76% / 5% | Fail |
It depends on the standard you follow. As of September 2026, MiMedx Group, Inc. (MDXG) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. MiMedx Group, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.76% of each dividend: MiMedx Group, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.